FDA approves quicker drug for blood cancers

U.S. regulators have approved a more convenient version of a blockbuster drug for treating three common blood cancers. The Roche Group’s Rituxan, on the market for 20 years, is administered in a hospital or clinic through an intravenous drip that can take several hours. On Thursday, the Food and Drug Administration approved the Swiss drugmaker’s new version, Rituxan Hycela (RIH’-tux-en HEYE’-cell-uh). It’s injected in about six minutes, shortening clinic visits. It’s given every three weeks for ...

Share this post